These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28698198)

  • 21. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
    Zhu Y; Liu C; Nadiminty N; Lou W; Tummala R; Evans CP; Gao AC
    Mol Cancer Ther; 2013 Sep; 12(9):1829-36. PubMed ID: 23861346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
    de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
    Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
    de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
    Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel.
    Kathawala RJ; Wang YJ; Shukla S; Zhang YK; Alqahtani S; Kaddoumi A; Ambudkar SV; Ashby CR; Chen ZS
    Chin J Cancer; 2015 Mar; 34(3):115-20. PubMed ID: 25962593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
    Hillowe A; Gordon C; Wang L; Rizzo RC; Trotman LC; Ojima I; Bialkowska A; Kaczocha M
    PLoS One; 2023; 18(10):e0292483. PubMed ID: 37796964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation.
    Liu L; Li M; Zhang J; Xu D; Guo Y; Zhang H; Cang S
    Arch Biochem Biophys; 2023 Mar; 737():109551. PubMed ID: 36822388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs.
    Wang Y; Huang Z; Chen CZ; Liu C; Evans CP; Gao AC; Zhou F; Chen HW
    Mol Cancer Ther; 2020 Feb; 19(2):364-374. PubMed ID: 31712394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical profile of cabazitaxel.
    Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
    Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
    Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
    Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
    Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
    Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
    Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer.
    Archer M; Begemann D; Gonzalez-Kozlova E; Nepali PR; Labanca E; Shepherd P; Dogra N; Navone N; Kyprianou N
    Mol Cancer Res; 2024 Aug; 22(8):730-745. PubMed ID: 38648082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer.
    Chen F; Wu S; Kuang N; Zeng Y; Li M; Xu C
    FEBS J; 2024 Jul; 291(14):3249-3266. PubMed ID: 38712529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of resistance to cabazitaxel.
    Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
    Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
    Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.